The newly approved indication allows two of Medtronic’s cardiac resynchronization pacemakers and eight cardiac resynchronization defibrillators to be used in patients with atrioventricular block and moderate, mild or severe heart failure, as well as providing pacing on both sides of the heart.
Clinical trials demonstrated a 27 percent reduction in death, heart failure-related urgent care visits and an increase in left ventricular end systolic volume index, a diagnostic measure of cardiac structure and function, according to an FDA news release.
More Articles on FDA Approvals:
FDA Approves Pradaxa for Deep Venous Thrombosis & Pulmonary Embolism
FDA Approves Alprolix for Hemophilia B Treatment
FDA Approves Otezla for Psoriatic Arthritis Treatment
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
